Treatment of Other Cancers
~ Genetics of Breast & Ovarian Cancer

Treatment of HBOC- or BRCA1/2 mutation-related cancers other than breast, ovarian, pancreatic, and prostate cancers; See other sections focused on those cancers individually.

List was last updated on Sep 3, 2020 @ 2:37 pm.


    • PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
    • Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G.
    • Medicines (Basel). 2020 Aug 31;7(9):E54. doi: 10.3390/medicines7090054.
    • Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    • Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.
    • BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
    • BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.
    • Premnath N, O'Reilly EM.
    • Chin Clin Oncol. 2020 Aug 10:cco-2019-ddp-05. doi: 10.21037/cco-2019-ddp-05. Epub ahead of print.
    • BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing.
    • Marchetti C, Minucci A, Pietragalla A, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2020 Aug 4:ijgc-2020-001670. doi: 10.1136/ijgc-2020-001670. Epub ahead of print.

    Guidelines:

    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

    • Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
    • Martin-Romano P, Ammari S, El-Dakdoukti Y, Baldini C, Varga A, Vuagnat P, Angevin E, Bahleda R, Gazzah A, Champiat S, Michot JM, Postel-Vinay S, Marabelle A, Soria JC, Boige V, Malka D, Ducreux M, Massard C, Hollebecque A.
    • Eur J Cancer. 2020 Aug 1;137:117-126. doi: 10.1016/j.ejca.2020.06.030. Epub ahead of print.
    • Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models.
    • Koustas E, Karamouzis MV, Sarantis P, Schizas D, Papavassiliou AG.
    • J Cell Mol Med. 2020 Jul 20. doi: 10.1111/jcmm.15655. Epub ahead of print.
    • Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report.
    • Xiong F, Gong J, Wang Q.
    • Onco Targets Ther. 2020 Jul 1;13:6385-6391. doi: 10.2147/OTT.S250454.
    • Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.
    • Zhu M, Mohamad S, Halfdanarson T, Hobday T, Ahn D, Ma WW, Bekaii-Saab T.
    • Oncologist. 2020 Jun 8. doi: 10.1634/theoncologist.2020-0029. Epub ahead of print.
    • Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    • Brönimann S, Lemberger U, Bruchbacher A, Shariat SF, Hassler MR.
    • Curr Opin Urol. 2020 May 13. doi: 10.1097/MOU.0000000000000776. Epub ahead of print.
    • Review
    • Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors.
    • Akhavanfard S, Padmanabhan R, Yehia L, Cheng F, Eng C.
    • Nat Commun. 2020 May 5;11(1):2206. doi: 10.1038/s41467-020-16067-1.

    Research news: Pediatric Cancer Patients With Solid Tumors Have Many Druggable Germline Alterations. (GenomeWeb)

    • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
    • Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.
    • JCO Precis Oncol. 2020;4:442. doi: 10.1200/PO.19.00345. Epub 2020 Apr 30.
    • Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
    • Amaral T, Schulze M, Sinnberg T, Nieser M, Martus P, Battke F, Garbe C, Biskup S, Forschner A.
    • Cancers (Basel). 2020 Apr 28;12(5). pii: E1101. doi: 10.3390/cancers12051101.
    • Mucinous Histology, BRCA1/2 Mutations, and Elevated Tumor Mutational Burden in Colorectal Cancer.
    • Harpaz N, Gatt YE, Granit RZ, Fruchtman H, Hubert A, Grinshpun A.
    • J Oncol. 2020 Apr 25;2020:6421205. doi: 10.1155/2020/6421205. eCollection 2020.
    • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    • Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM.
    • J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27.

    Commentary:

    BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing.

    • Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report.
    • Inoue K, Tsubamoto H, Ueda T, Tajima C, Nakagomi N.
    • Gynecol Oncol Rep. 2020 Apr 5;32:100563. doi: 10.1016/j.gore.2020.100563. eCollection 2020 May.
    • An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube.
    • Boltežar L, Gašljevic G, Novakovic S, Stegel V, Škof E.
    • Hered Cancer Clin Pract. 2020 Mar 19;18:7. doi: 10.1186/s13053-020-00139-w. eCollection 2020.
    • [Medical treatment options in BRCA-associated cancers].
    • Kahán Z.
    • Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.
    • Review, [Article in Hungarian]
    • Small Cell Carcinoma of the Ovary, Hypercalcaemic Type - genetics, new treatment targets and current management guidelines.
    • Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks WPD, Huntsman DG, Lang JD, Orlando KA, Oza AM, Pautier P, Ray-Coquard I, Trent JM, Wichter M, Witkowski L, McCluggage WG, Levine DA, Foulkes WD, Weissman BE.
    • Clin Cancer Res. 2020 Mar 10. pii: clincanres.3797.2019. doi: 10.1158/1078-0432.CCR-19-3797. [Epub ahead of print]
    • Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.
    • Ahn DH, Bekaii-Saab T.
    • Chin Clin Oncol. 2020 Feb;9(1):6. doi: 10.21037/cco.2020.02.02. Epub 2020 Feb 20.
    • Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
    • Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.
    • Oncologist. 2020 Feb;25(2):e198-e202. doi: 10.1634/theoncologist.2019-0603. Epub 2019 Oct 16.
    • An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome.
    • Talreja VT, Noronha V, Joshi A, Patil V, Prabhash K.
    • South Asian J Cancer. 2020 Jan-Mar;9(1):6. doi: 10.4103/sajc.sajc_157_19.
    • Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    • Connor YD, Miao D, Lin DI, Hayne C, Howitt BE, Dalrymple JL, DeLeonardis KR, Hacker MR, Esselen KM, Shea M.
    • Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618-X. doi: 10.1016/j.ygyno.2019.10.031. [Epub ahead of print]
    • Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
    • Exman P, Mallery RM, Lin NU, Parsons HA.
    • NPJ Breast Cancer. 2019 Nov 29;5:46. doi: 10.1038/s41523-019-0139-1. eCollection 2019.
    • Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer.
    • Wen L, Li X, Shi J, Zhang S, Wang R, Yao M, Guo J.
    • J Int Med Res. 2019 Nov 27:300060519886226. doi: 10.1177/0300060519886226. [Epub ahead of print]
    • Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.
    • Principe DR, Kamath SD, Munshi HG, Mohindra NA.
    • Oncologist. 2019 Nov 1. pii: theoncologist.2019-0393. doi: 10.1634/theoncologist.2019-0393. [Epub ahead of print]
    • Case report, Review
    • Apatinib as Salvage Treatment in BRCA2-Mutated Advanced Lung Adenocarcinoma.
    • Zeng DX, Huang JA, Jiang JH.
    • Am J Ther. 2019 Nov/Dec;26(6):e747-e748. doi: 10.1097/MJT.0000000000000905.
    • Case report
    • Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report.
    • Mariniello A, Ghisoni E, Righi L, Catino A, Chiari R, Del Conte A, Barbieri F, Cecere F, Gelibter A, Giajlevra M, Parra HS, Zichi C, DI Maio M, Valabrega G, Novello S.
    • In Vivo. 2019 Nov-Dec;33(6):2021-2026. doi: 10.21873/invivo.11699.
    • Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
    • Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.
    • Oncologist. 2019 Oct 16. pii: theoncologist.2019-0603. doi: 10.1634/theoncologist.2019-0603. [Epub ahead of print]
    • Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    • Kadouri L, Rottenberg Y, Zick A, Hamburger T, Lipson D, Peretz T, Nechushtan H.
    • Lung Cancer. 2019 Sep 12;137:48-51. doi: 10.1016/j.lungcan.2019.09.008. [Epub ahead of print]
    • Germline BRCA-associated Endometrial Carcinoma is a Distinct Clinicopathologic Entity.
    • de Jonge MM, Ritterhouse LL, de Kroon CD, Vreeswijk MPG, Segal JP, Puranik R, Study H, Hollema H, Rookus MA, van Asperen CJ, Van Leeuwen FE, Smit VTHBM, Howitt BE, Bosse T.
    • Clin Cancer Res. 2019 Sep 6. pii: clincanres.0848.2019. doi: 10.1158/1078-0432.CCR-19-0848. [Epub ahead of print]
    • Precision medicine for metastatic colorectal cancer: an evolving era.
    • Guler I, Askan G, Klostergaard J, Sahin IH.
    • Expert Rev Gastroenterol Hepatol. 2019 Aug 31. doi: 10.1080/17474124.2019.1663174. [Epub ahead of print]
    • Review
    • A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
    • Beetham H, Chen A, Telford BJ, Single A, Jarman KE, Lackovic K, Luxenburger A, Guilford P.
    • Sci Rep. 2019 Aug 29;9(1):12511. doi: 10.1038/s41598-019-48929-0.
    • Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
    • Beulque Y, Deleu AL, Punie K, De Wever L, Baldewijns M, Caruso S, Couchy G, Zucman-Rossi J, Beuselinck B.
    • Clin Genitourin Cancer. 2019 Jul 11. pii: S1558-7673(19)30202-2. doi: 10.1016/j.clgc.2019.06.013. [Epub ahead of print]
    • Case report
    • Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation.
    • Snow A, Ricker C, In GK.
    • BMJ Case Rep. 2019 Jun 20;12(6). pii: e227625. doi: 10.1136/bcr-2018-227625.
    • Case report
    • Endometrial cancers in BRCA1 or BRCA2 germline mutations carriers.
    • Smith E, Paula ADC, Mandelker D, Weigelt B.
    • Gynecol Oncol. 2019 Jun;153(3):e8-e9. doi: 10.1016/j.ygyno.2019.03.125.
    • Conference abstract
    • Alterations in DNA damage repair genes in primary liver cancer.
    • Lin J, Shi J, Guo H, Yang X, Jiang Y, Long J, Bai Y, Wang D, Yang X, Wan X, Zhang L, Pan J, Hu K, Guan M, Huo L, Sang X, Wang K, Zhao H.
    • Clin Cancer Res. 2019 May 8. pii: clincanres.0127.2019. doi: 10.1158/1078-0432.CCR-19-0127. [Epub ahead of print]
    • Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes.
    • Ged Y, Chen YB, Knezevic A, Donoghue MTA, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Voss MH, Motzer RJ.
    • Clin Genitourin Cancer. 2019 May 2. pii: S1558-7673(19)30132-6. doi: 10.1016/j.clgc.2019.04.006. [Epub ahead of print]
    • Case report
    • Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes.
    • Wong W, Lowery MA, Berger MF, Kemel Y, Taylor B, Zehir A, Srinivasan P, Bandlamudi C, Chou J, Capanu M, Varghese A, Yu KH, Iacobuzio-Donahue CA, Shia J, Klimstra DS, Jarnagin WR, Stadler ZK, O'Reilly EM.
    • Cancer. 2019 May 1;125(9):1441-1448. doi: 10.1002/cncr.31951. Epub 2019 Jan 8.
    • Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.
    • Yan T, Cui H, Zhou Y, Yang B, Kong P, Zhang Y, Liu Y, Wang B, Cheng Y, Li J, Guo S, Xu E, Liu H, Cheng C, Zhang L, Chen L, Zhuang X, Qian Y, Yang J, Ma Y, Li H, Wang F, Liu J, Liu X, Su D, Wang Y, Sun R, Guo S, Li Y, Cheng X, Liu Z, Zhan Q, Cui Y.
    • Nat Commun. 2019 Apr 11;10(1):1670. doi: 10.1038/s41467-019-09255-1.
    • Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
    • Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S.
    • Nat Commun. 2019 Apr 9;10(1):1635. doi: 10.1038/s41467-019-09633-9.
    • Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib.
    • Seto T, Pujare D, Song MN, Lee J, Huber R, Sam D, Pan M.
    • J Oncol Pract. 2019 Apr 2:JOP1800708. doi: 10.1200/JOP.18.00708. [Epub ahead of print]
    • Case report
    • E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
    • Godwin TD, Kelly ST, Brew TP, Bougen-Zhukov NM, Single AB, Chen A, Stylianou CE, Harris LD, Currie SK, Telford BJ, Beetham HG, Evans GB, Black MA, Guilford PJ.
    • Gastric Cancer. 2019 Mar;22(2):273-286. doi: 10.1007/s10120-018-0859-1. Epub 2018 Jul 31.
    • Family History of Breast Cancer Associated with Breast Cancer in Survivors of Hodgkin Lymphoma.
    • Colonna S, Curtin K, Johnson E, Kohlmann W, Wright J, Kirchhoff A, Tavtigian S, Schiffman J.
    • Int J Cancer Clin Res. 2019;6(1). pii: 107. doi: 10.23937/2378-3419/1410107. Epub 2019 Feb 25.
    • Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report.
    • Lin Z, Liu J, Peng L, Zhang D, Jin M, Wang J, Xue J, Liu H, Zhang T.
    • BMC Cancer. 2018 Dec 14;18(1):1253. doi: 10.1186/s12885-018-5182-z.
    • BRCA Mutation and Its Association With Colorectal Cancer.
    • Soyano AE, Baldeo C, Kasi PM.
    • Clin Colorectal Cancer. 2018 Dec;17(4):e647-e650. doi: 10.1016/j.clcc.2018.06.006. Epub 2018 Jul 3.
    • BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine.
    • Tlemsani C, Pasmant E, Boudou-Rouquett P, Bellesoeur A, Even J, Larousserie F, Reyes C, Gentien D, Alexandre J, Vidaud M, Anract P, Leroy K, Goldwasser F.
    • Am J Med Sci. 2018 Oct;356(4):404-407. doi: 10.1016/j.amjms.2018.04.015. Epub 2018 May 1.
    • Case report, Review
    • Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report.
    • Cheng Y, Zhang J, Qin SK, Hua HQ.
    • Onco Targets Ther. 2018 Sep 18;11:5957-5962. doi: 10.2147/OTT.S176914. eCollection 2018.
    • Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
    • Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK.
    • Oncologist. 2018 Sep;23(9):998-1003. doi: 10.1634/theoncologist.2017-0645. Epub 2018 Apr 5.
    • Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
    • Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V4, Vivancos A.
    • J Natl Cancer Inst. 2018 Aug 1;110(8):914-917. doi: 10.1093/jnci/djy012.
    • Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
    • Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA, Konstantinopoulos PA.
    • Gynecol Oncol. 2018 Aug;150(2):219-226. doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.
    • Case report
    • Pathogenic germline BRCA1/2 mutations and familial predisposition to gastric cancer.
    • Ichikawa H, Wakai T, Nagahashi M, Shimada Y, Hanyu T, Kano Y, Muneoka Y, Ishikawa T, Takizawa K, Tajima Y, Sakata J, Kobayashi T, Kemeyama H, Yabusaki H, Nakagawa S, Sato N, Kawasaki T, Homma K, Okuda S, Lyle S, Takabe K.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00097. Epub 2018 Jul 5.
    • Impact of BRCA mutations on outcomes among patients with serous endometrial cancer.
    • Kadan Y, Raviv O, Segev Y, Lavie O, Bruchim I, Fishman A, Michaelson R, Beller U, Helpman L.
    • Int J Gynaecol Obstet. 2018 Jul;142(1):91-96. doi: 10.1002/ijgo.12486. Epub 2018 Apr 2.
    • Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.
    • Necchi A, Raggi D, Giannatempo P, Alessi A, Serafini G, Colecchia M, Ali SM, Chung JH.
    • Eur J Cancer. 2018 Jun;96:128-130. doi: 10.1016/j.ejca.2018.03.021. Epub 2018 Apr 18.
    • Case report, Letter
    • Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation.
    • Dizon DS, Dias-Santagata D, Bregar A, Sullivan L, Filipi J, DiTavi E, Miller L, Ellisen L, Birrer M, DelCarmen M.
    • Oncologist. 2018 Jun;23(6):650-653. doi: 10.1634/theoncologist.2017-0526. Epub 2018 Feb 22.
    • Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
    • Quaas A, Waldschmidt D, Alakus H, Zander T, Heydt C, Goeser T, Daheim M, Kasper P, Plum P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Göbel H, Tharun L, Buettner R, Merkelbach-Bruse S.
    • BMC Gastroenterol. 2018 May 31;18(1):75. doi: 10.1186/s12876-018-0803-1.
    • Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
    • Fan FS, Yang CF.
    • J Med Case Rep. 2018 May 6;12(1):122. doi: 10.1186/s13256-018-1674-3.
    • Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature.
    • Herold N, Wappenschmidt B, Markiefka B, Keupp K, Kröber S, Hahnen E, Schmutzler R, Rhiem K.
    • Oncol Lett. 2018 Apr;15(4):4093-4096. doi: 10.3892/ol.2018.7836. Epub 2018 Jan 22.
    • Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.
    • Mihailidou C, Karamouzis MV, Schizas D, Papavassiliou AG.
    • Biochimie. 2017 Nov;142:135-143. doi: 10.1016/j.biochi.2017.09.001. Epub 2017 Sep 7.
    • Review
    • Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan.
    • Yi JS, Kamihara J, Kesselheim JC, Davies K, van Hoff J, Silverman LB, Mullen EA.
    • Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26345. Epub 2016 Nov 15.
    • Case report
    • Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.
    • Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT.
    • World J Gastroenterol. 2016 Dec 14;22(46):10254-10259. doi: 10.3748/wjg.v22.i46.10254.
    • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.
    • Weinberger V, Bednarikova M, Cibula D, Zikan M.
    • Expert Rev Anticancer Ther. 2016 Dec;16(12):1311-1321. Epub 2016 Oct 22.
    • Review
    • Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.
    • Miolo G, Viel A, Canzonieri V, Baresic T, Buonadonna A, Santeufemia DA, Lara DP, Corona G.
    • Cancer Biol Ther. 2016 Oct 2;17(10):1017-1021.
    • Case report
    • Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.
    • Moiseyenko VM, Volkov NM, Suspistin EN, Yanus GA, Iyevleva AG, Kuligina ESh, Togo AV, Kornilov AV, Ivantsov AO, Imyanitov EN.
    • Med Oncol. 2013 Jun;30(2):545. doi: 10.1007/s12032-013-0545-4. Epub 2013 Mar 27.